Zydus receives final approval from the USFDA for Efinaconazole Topical Solution

Zydus Lifesciences Limited's (formerly known as Cadila Healthcare Limited) subsidiary Zydus Worldwide DMCC has received final approval from the United States Food and Drug Administration (USFDA) to market Efinaconazole Topical Solution, 10%. (US RLD: Jublia®).

Efinaconazole is an azole antifungal used for the topical treatment of Onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes. The drug will be manufactured at the group's topical manufacturing facility at, Ahmedabad, India.

Jublia® (Efinaconazole) topical solution, 10% had annual sales of $292 million in the United States according to IQVIA data (IQVIA MAT May 2022).

The group now has 317 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2022)

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 358.20 as compared to the previous close of Rs. 371.15. The total number of shares traded during the day was 180611 in over 5324 trades.

The stock hit an intraday high of Rs. 372.30 and intraday low of 356.65. The net turnover during the day was Rs. 65469253.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA EfinaconazoleTopicalSolution